U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06858995) titled 'Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)' on Feb. 28.
Brief Summary: According to Pluvicto(R) indication, most of patients treated are elderly, with limited/poor venous peripheric access but they received previously chemotherapy through TIVAP and TIVAP generally stays in the body of patients when they are referred for Pluvicto(R) therapy. This is why TIVAP could be an interesting alternative for administering of 177Lu-PSMA-617. The aim of this study is to assess potential retention of 177Lu-PSMA-617 on TIVAP during administration through in vitro/ex vivo experimentations then in in vivo analysis.
Study ...